Clinical and epidemiological features of acute lymphoblastic leukemia following a previous malignancy.

Abstract:

:Secondary malignancies represent a relevant complication of chemotherapy employed for a previous cancer. Acute leukemias represent the most frequent secondary malignancy in the first decade following primary neoplasms; secondary leukemias are generally myeloid and can be preceeded by a myelodysplastic syndrome. The biological and epidemiological characteristics of secondary acute myeloid are well known and have been the subject of numerous reports and reviews in the last few years. The observation of a secondary acute lymphoblastic leukemia is considered rare, and the correlation with antecedent therapies is not definitive. Most of reported cases are single reports, and no large study has been performed to investigate the real importance of this problem. In this review we report data of the current literature on secondary acute lymphoblastic leukemia, both in adults and children, in order to analyze its incidence and clinical and laboratory features.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Pagano L,Pulsoni A,Mele L,Leone G

doi

10.3109/10428190009113377

keywords:

subject

Has Abstract

pub_date

2000-11-01 00:00:00

pages

465-75

issue

5-6

eissn

1042-8194

issn

1029-2403

pii

I308J001154

journal_volume

39

pub_type

杂志文章,评审
  • Are alkylating agents a necessary component in the therapy of Hodgkin's disease.

    abstract::Management of early stages of Hodgkin's disease requires development of treatment programs that are nominally toxic, with a low likelihood of sterility and secondary malignancies, both associated with alkylating agents. Although patients with laparotomy-staged disease without B symptoms or large mediastinal masses hav...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309149119

    authors: Hagemeister FB

    更新日期:1993-01-01 00:00:00

  • Rapid Remission Induction and Improved Disease Free Survival in Acute Myeloid Leukaemia Using Daunorubicin, ARA-C, and CCNU.

    abstract::Thirty-four patients with acute myeloblastic leukaemia were treated with DAC, a schedule containing the nitrosourea CCNU (lomustine) 200 mg/m2 given on day one of treatment, together with a standard "3 + 7" remission induction schedule of daunorubicin (DR) and cytosine arabinoside (Ara-C). The results were compared wi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009050988

    authors: Barrett AJ,Treleaven JG,Samson DM,Evans M,Gaminara E,Foadi M,McCarthy DM

    更新日期:1990-01-01 00:00:00

  • Clinical significance of pre- and 1-year post-transplant serum ferritin among adult transplant recipients.

    abstract::To clarify the significance of post-transplant serum ferritin (SF), we retrospectively assessed pre- and post-transplant SF. Among 256 patients undergoing allogeneic stem cell transplant (SCT) for hematologic malignancies between 2000 and 2011, those who had relapsed within 1 year were excluded, and 110 patients survi...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.842981

    authors: Tachibana T,Tanaka M,Numata A,Matsumoto K,Tomita N,Fujimaki K,Taguchi J,Sakai R,Fujita H,Fujisawa S,Maruta A,Ishigatsubo Y,Kanamori H

    更新日期:2014-06-01 00:00:00

  • T cell receptor V beta repertoires of angioimmunoblastic lymphadenopathy-like T cell lymphoma.

    abstract::To elucidate the pathogenesis of angioimmunoblastic lymphadenopathy-like T cell lymphoma (AILD-T) we investigated the T cell receptor V beta gene repertoires of four AILD-Ts and compared them with those of other histological types of lymphomas and three cases with reactive disorders. All lymphoma patients had rearrang...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409114150

    authors: Araki A,Taniguchi M,Mikata A

    更新日期:1994-12-01 00:00:00

  • Resistance to apoptosis induced by serum depletion and all-trans retinoic acid in drug-resistant leukemic cell lines.

    abstract::The relation between resistance to anticancer drugs and resistance to apoptosis has been investigated in the human leukemic cell line(KY-821) and its drug-resistant sublines. Under serum depletion conditions, drug-resistant cell lines showed apoptotic resistance when compared with the parental cell line. Drug resistan...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709051787

    authors: Kakihara T,Fukuda T,Kamishima T,Naito M,Tanaka A,Uchiyama M,Kishi K

    更新日期:1997-07-01 00:00:00

  • HIV-related non-Hodgkin's lymphoma: CHOP induction therapy and interferon-alpha-2b/zidovudine maintenance therapy.

    abstract::In a prospective multicenter study 68 out of 158 patients with HIV infection and malignant lymphoma were assigned to a risk-adapted induction therapy using the following algorithm: High-risk patients fulfilled 2 of 3 criteria: T4 lymphocytes <50/microL; WHO activity index 3 or 4; pre-existing AIDS-defining opportunist...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428199809058386

    authors: Weiss R,Huhn D,Mitrou P,Nerl C,Schürmann D,Scheidegger C,Knauf W,Trenn G,Kronawitter U,Van Lunzen J,Arastéh K,Herbst H

    更新日期:1998-03-01 00:00:00

  • Treatment of advanced Hodgkin's disease: EBVD versus intensive brief chemotherapy.

    abstract::We start a controlled clinical trial to assess efficacy and toxicity of EBVD (epirubicin, bleomycin, vinblastine and dacarbazine) with an intensive and brief program of seven drugs administered weekly for 12 weeks in previously untreated patients with advanced Hodgkin's disease. Two hundred and sixty four patients wer...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1080/1042819031000067729

    authors: Avilés A,Cleto S,Neri N,Huerta-Guzmán J,Talavera A,Castañeda C,González M

    更新日期:2003-08-01 00:00:00

  • Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells.

    abstract::Bone marrow mesenchymal stromal cells (MSCs) can rescue acute lymphoblastic leukemia (ALL) cells from L-asparaginase by replenishing the depleted asparagine. As both vincristine (VCR) and imatinib mesylate (IM) can inhibit MSCs' proliferation, we hypothesized that these drugs might reduce the niche support of MSCs to ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903406798

    authors: Fung KL,Liang RH,Chan GC

    更新日期:2010-03-01 00:00:00

  • Hepatitis C virus, B-cell proliferation and lymphomas.

    abstract::Accumulating evidence support a role for hepatitis C virus (HCV) in the pathogenesis of human lymphoproliferative disorders. Clonal expansions of B lymphocytes have been prevalently detected in the bone marrow, in the liver and in the peripheral blood of HCV-infected patients. Epidemiologic studies have associated HCV...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190290016845

    authors: Gasparotto D,De Re V,Boiocchi M

    更新日期:2002-04-01 00:00:00

  • Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.

    abstract::Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin lymphomas that typically present in the skin but can progress to systemic involvement. The optimal treatment for patients who relapse from or are refractory to systemic chemotherapy remains unclear. Romidepsin is a potent, class-I selective histone deacetyla...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2017.1361022

    authors: Duvic M,Bates SE,Piekarz R,Eisch R,Kim YH,Lerner A,Robak T,Samtsov A,Becker JC,McCulloch W,Waksman J,Whittaker S

    更新日期:2018-04-01 00:00:00

  • A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma.

    abstract::The standard CHOP regimen may cure 30-40% of patients with advanced aggressive non-Hodgkin's lymphoma (ANHL). Mitoxantrone is an anthracenedione, which is active in NHL and its toxicity profile may be more favorable than doxorubicin with respect to alopecia, mucositis and cardiotoxicity. This study was designed to com...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1080/1042819031000063471

    authors: Pangalis GA,Vassilakopoulos TP,Michalis E,Roussou P,Vrakidou E,Repousis P,Angelopoulou MK,Siakantaris MP,Korantzis J,Symeonidis A,Grigorakis V,Stefanoudakis E,Stamatellou M,Bourantas KL,Kalmantis T,Christopoulos G,Kokkini

    更新日期:2003-04-01 00:00:00

  • Chromosomal instability and ATR amplification gene in patients with persistent and polyclonal B-cell lymphocytosis (PPBL).

    abstract::Forty-three patients with persistent and polyclonal B-cell lymphocytosis (PPBL) were studied. The PPBL diagnosis was based on the presence of a polyclonal lymphocytosis and the detection of binucleated lymphoid cells on peripheral blood examination. In order to define the cytogenetic profile in these patients, convent...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194042000191738

    authors: Mossafa H,Tapia S,Flandrin G,Troussard X,Groupe Français d'Hématologie Cellulaire (GFHC).

    更新日期:2004-07-01 00:00:00

  • Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.

    abstract::Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymph...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190210178

    authors: Perz J,Topaly J,Fruehauf S,Hensel M,Ho AD

    更新日期:2002-01-01 00:00:00

  • Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis.

    abstract::Recently, lenalidomide and low dose dexamethasone were found to result in superior overall survival compared to lenalidomide and high dose dexamethasone. The immune suppressive effects of dexamethasone can antagonize lenalidomide immunomodulatory activity and may explain this observation. We conducted a retrospective ...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428191003721342

    authors: Baz R,Patel M,Finley-Oliver E,Lebovic D,Hussein MA,Miller KC,Wood M,Sher T,Lee K,Chanan-Khan AA

    更新日期:2010-06-01 00:00:00

  • Lack of CD54 expression and mutation of p53 gene relate to the prognosis of childhood Burkitt's lymphoma.

    abstract::Expression of the intercellular adhesion molecule-1 (CD54) as well as the mutations of p53 gene were studied in childhood Burkitt's lymphoma (BL). Expression of CD54 was identified in 6 of 15 fresh BL cases. Mutations of p53 gene, analyzed by polymerase chain reaction-single stranded chain polymorphism followed by seq...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609093443

    authors: Kaneko H,Sugita K,Kiyokawa N,Iizuka K,Takada K,Saito M,Yoshimoto K,Itakura M,Kokai Y,Fujimoto J

    更新日期:1996-05-01 00:00:00

  • Richter's syndrome in the brain first manifested as an ischaemic stroke.

    abstract::Isolated central nervous system involvement in Richter's syndrome (RS) is extremely rare and only 6 such cases have been described, so far. We report a 60-year-old woman with B-cell chronic lymphocytic leukemia (B-CLL) heavily pretreated with cladribine based regimens and rituximab in whom RS in the brain was first ma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001638823

    authors: Robak T,Góra-Tybor J,Tybor K,Jamroziak K,Robak P,Kordek R,Rieske P,Majos A,Urbańska-Ryś H

    更新日期:2004-06-01 00:00:00

  • Surrogate end points for long-term outcomes in chronic myeloid leukemia.

    abstract::The natural history of the chronic phase (CP) of chronic myeloid leukemia (CML) and the high response rates achieved with BCR-ABL inhibitor therapy necessitate long-term evaluation of survival-based outcome measures. Prior to the availability of long-term BCR-ABL inhibitor data, short-term surrogate end points predict...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2013.772607

    authors: Akwaa F,Liesveld J

    更新日期:2013-10-01 00:00:00

  • Treatment of minimal residual disease in myeloid leukemia--the immunotherapeutic options with emphasis on Linomide.

    abstract::It is now known that syngeneic transplantation, T lymphocyte depletion and absence of graft-versus-host disease all increase the risk of relapse following allogeneic transplantation for the myeloid leukemias, both acute and chronic. Leukemia-specific immune responses appear to play a major role in the therapy of the m...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309067922

    authors: Rowe JM,Nilsson BI,Simonsson B

    更新日期:1993-11-01 00:00:00

  • Biological features of leukaemic cells associated with autonomous growth and reduced survival in acute myeloblastic leukaemia.

    abstract::The blast cells from up to 70% of patients with acute myeloblastic leukaemia exhibit a variable degree of autonomous growth in vitro, which is related to the production of autocrine growth factors. It has recently been established that patients with autonomous blast cell growth have both a lower remission rate and a h...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509049761

    authors: Russell NH,Hunter AE,Bradbury D,Zhu YM,Keith F

    更新日期:1995-01-01 00:00:00

  • Up-regulation of tissue inhibitor of metalloproteinase-2 promotes SHI-1 cell invasion in nude mice.

    abstract::The role of tissue inhibitor of metalloproteinase-2 (TIMP-2) in extramedullary infiltration of acute leukemia is unclear. We demonstrated in our previous study that the up-regulation of TIMP-2 promoted SHI-1 cell invasion in vitro. We investigated in the present study whether TIMP-2 would have the same effect in vivo....

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2013.783214

    authors: Wang C,Cai X,Chen B,He Z,Chen Z,Cen J,Li Z

    更新日期:2013-12-01 00:00:00

  • Impact of clinical factors on outcome of leukemia patients with TLS-ERG fusion gene.

    abstract::We report the clinical features and outcome of 22 TLS-ERG+ leukemia patients (20 AML and 2 B-ALL). TLS-ERG was tightly associated with extramedullary disease (EMD), complex chromosome abnormalities, and high risk gene mutations including IKZF1, WT1, TET2, NOTCH2, and PHF6. The 6-month leukemia free survival (LFS) with...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1260124

    authors: Pan J,Zhang Y,Zhao YL,Yang JF,Zhang JP,Liu HX,Wu T,Tong CR

    更新日期:2017-07-01 00:00:00

  • The G protein-coupled receptor CysLT1 mediates chemokine-like effects and prolongs survival in chronic lymphocytic leukemia.

    abstract::The G protein-coupled receptor (GPCR) CXCR4 is involved in bone marrow tropism and survival of chronic lymphocytic leukemia (CLL) cells. The function of the GPCRs cysteinyl leukotriene receptor 1 (CysLT1) and CysLT2 remains elusive. Here we demonstrate that in CLL and normal B lymphocytes, CysLT1 mRNA is consistently ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.625578

    authors: Drost AC,Seitz G,Boehmler A,Funk M,Norz KP,Zipfel A,Xue X,Kanz L,Möhle R

    更新日期:2012-04-01 00:00:00

  • Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.

    abstract::The aim of the study was efficacy and toxicity evaluation of combination of 2-Chlorodeoxyadenosine (2-CdA) with cytarabine (Ara-C) and G-CSF (CLAG regimen) as reinduction therapy in patients with refractory or relapsed acute myeloid leukemia (AML). The protocol stipulated an infusion of 5 mg/m2 of 2-CdA over 2 hours d...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009053545

    authors: Robak T,Wrzesień-Kuś A,Lech-Marańda E,Kowal M,Dmoszyńska A

    更新日期:2000-09-01 00:00:00

  • Primary hematolymphoid malignancies involving the extrahepatic bile duct or gallbladder.

    abstract::Primary hematolymphoid malignancies of the extrahepatic biliary tract are rare tumors. We report five cases of primary hematolymphoid malignancies involving the extrahepatic biliary tract. One is a granulocytic sarcoma of the extrahepatic bile duct, another is an extramedullary plasmacytoma of the gallbladder, and the...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.483300

    authors: Hwang DW,Lim CS,Jang JY,Lee SE,Yoon SO,Jeon YK,Uk Lee K,Kim SW

    更新日期:2010-07-01 00:00:00

  • Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma.

    abstract::The prednisone, etoposide, procarbazine and cyclophosphamide (PEP-C) oral combination chemotherapy regimen (prednisone 20 mg, cyclophosphamide 50 mg, etoposide 50 mg, and procarbazine 50 mg with an oral anti-emetic) was employed at our center to treat 22 patients with heavily pretreated, recurrent mantle cell lymphoma...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701837330

    authors: Coleman M,Martin P,Ruan J,Furman R,Niesvizky R,Elstrom R,George P,Leonard J,Kaufmann T

    更新日期:2008-03-01 00:00:00

  • Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene.

    abstract::Donor T cells have a critical role in promoting engraftment after allogeneic bone marrow transplantation (BMT), but also cause graft versus host disease (GVHD). Ex vivo T cell depletion has been an effective strategy to reduce GVHD but has been associated with impaired alloengraftment and host immunity. Using an MHC-m...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000016041

    authors: Drobyski WR,Gendelman M

    更新日期:2002-10-01 00:00:00

  • Activation-induced cytidine deaminase mRNA levels in chronic lymphocytic leukemia.

    abstract::The Rai and Binet staging systems, which are used as standard methods for evaluating the prognosis of chronic lymphocytic leukemia (CLL), have some restrictions in identifying patients with early-stage CLL who will progress rapidly. To solve this defect, other prognostic parameters have become important in recent year...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.531410

    authors: Hancer VS,Kose M,Diz-Kucukkaya R,Yavuz AS,Aktan M

    更新日期:2011-01-01 00:00:00

  • Ferritin as prognostic marker in multiple myeloma patients undergoing autologous transplantation.

    abstract::Serum ferritin reflects body iron stores, but this correlation is dissociated in inflammation. Ferritin has been shown to be prognostically relevant in breast cancer and in patients with hematologic malignancies undergoing autologous or allogeneic stem cell transplantation. In the present study, we evaluated the progn...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.891025

    authors: Strasser-Weippl K,Ludwig H

    更新日期:2014-11-01 00:00:00

  • Whole-exome sequencing reveals potential molecular predictors of relapse after discontinuation of the targeted therapy in chronic myeloid leukemia patients.

    abstract::Chronic myeloid leukemia (CML) is a myeloproliferative disease well treated by tyrosine kinase inhibitors (TKIs). The aim was to identify genes with a predictive value for relapse-free survival after TKI cessation in CML patients. We performed whole-exome sequencing of DNA from six CML patients in long-lasting deep mo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1132420

    authors: Smirnikhina SA,Lavrov AV,Chelysheva EY,Adilgereeva EP,Shukhov OA,Turkina A,Kutsev SI

    更新日期:2016-07-01 00:00:00

  • Acute promyelocytic leukemia in a HIV seropositive patient.

    abstract::Acute myeloid leukemia (AML) is infrequent in patients with human immunodeficiency virus (HIV) infection. Among AML, acute promyelocytic leukemia (APL) has been rarely described in such patients, with only one case being published. We report a 30 years-old intravenous drug abuser HIV-infected male with APL who attaine...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709050899

    authors: Calvo R,Ribera JM,Battle M,Sancho JM,Granada I,Flores A,Millá F,Feliu E

    更新日期:1997-08-01 00:00:00